阿拉斯加偏远社区SARS-CoV-2快速抗原检测的应用
阿拉斯加Yukon-Kuskokwim Delta地区因标本运送导致检测周转慢,2020年11月9日引入BinaxNOW快速抗原检测。分析54,981份抗原和分子检测结果发现,引入后检测周转时间从6.4天降至4.4天,每日发病率下降65%,表明即时快速抗原检测可缩短农村社区检测周转时间。
要点
- 偏远农村社区引入快速抗原检测可显著缩短SARS-CoV-2检测周转时间。
- BinaxNOW引入后每日发病率下降65%,有助于快速隔离和接触者追踪。
- 在实验室核酸检测不便的农村地区,即时快速抗原检测是有效工具。
核心结论
- 即时快速抗原检测可缩短农村社区SARS-CoV-2检测周转时间,并可能通过促进快速隔离、接触者追踪和本地缓解策略减少传播。
研究设计与样本
- 回顾性分析2020年9月15日至2021年3月1日期间在Yukon-Kuskokwim Delta地区进行的54,981份SARS-CoV-2抗原和分子检测结果。
主要发现
- 检测结果中位周转时间从2020年9月15日至11月8日的6.4天降至2020年11月9日至2021年3月1日的4.4天(p<0.001)。
- 引入快速即时检测后约1个月内,每日SARS-CoV-2病例率下降超过三倍,该时期在COVID-19疫苗接种引入之前。
临床怎么用
- 在实验室核酸检测不便的偏远农村社区,可使用即时快速抗原检测以缩短周转时间,促进快速隔离和接触者追踪。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Controlling the spread of SARS-CoV-2, the virus that causes COVID-19, in Alaska is challenging. Alaska includes many remote and isolated villages with small populations (ranging from 15 to >1,000 persons) that are accessible only by air from larger communities. Until rapid point-of-care testing became widely available, a primary challenge in the diagnosis of COVID-19 in rural Alaska was slow turnaround times for SARS-CoV-2 test results, attributable to the need to transport specimens to testing facilities. To provide more timely test results and isolation of cases, the Yukon Kuskokwim Health Corporation (YKHC) introduced Abbott BinaxNOW COVID-19 Ag rapid antigen test (BinaxNOW) on November 9, 2020, in the rural Yukon-Kuskokwim Delta region in southwestern Alaska. To evaluate the impact of implementing antigen testing, YKHC reviewed the results of 54,981 antigen and molecular tests for SARS-CoV-2 performed in the Yukon-Kuskokwim Delta during September 15, 2020-March 1, 2021. Introduction of rapid, point-of-care testing was followed by a more than threefold reduction in daily SARS-CoV-2 case rates during approximately 1 month before the introduction of COVID-19 vaccination. The median turnaround time for SARS-CoV-2 test results decreased by >30%, from 6.4 days during September 15-November 8, 2020, to 4.4 days during November 9, 2020-March 1, 2021 (p<0.001). Daily incidence decreased 65% after the introduction of BinaxNOW, from 342 cases per 100,000 population during the week of November 9 to 119 during the week of December 13 (p<0.001). These findings indicate that point-of-care rapid antigen testing can be a valuable tool in reducing turnaround times in rural communities where local access to laboratory-based nucleic acid amplification testing (NAAT) is not readily available and could thereby reduce transmission by facilitating rapid isolation of infected persons, contact tracing, and implementation of local mitigation strategies.
引用
- Hodges E, Lefferts B, Bates E, et al. Use of Rapid Antigen Testing for SARS-CoV-2 in Remote Communities - Yukon-Kuskokwim Delta Region, Alaska, September 15, 2020-March 1, 2021. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34411078. doi:10.15585/mmwr.mm7033a3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。